IRLA QUINCE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, QUINCE THERAPEUTICS INC reported revenue of n/a, net income of −$75.5M and diluted EPS of −$12.31; for the fiscal year ended December 2025 revenue was n/a.
IRLA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$58.1M, net income −$84.0M (margin n/a), EPS −$1.68
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$57.3M, net income −$56.8M (margin n/a), EPS −$1.31
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$34.6M, net income −$31.4M (margin n/a), EPS −$0.84
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$52.0M, net income −$51.7M (margin n/a), EPS −$1.54
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$90.3M, net income −$89.9M (margin n/a), EPS −$3.03
IRLA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$75.5M, EPS −$12.31
- Quarter ended Mar 31, 2026: revenue n/a, net income $35.9M, EPS $2.88
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$39.5M, EPS $70.74
- Quarter ended Sep 30, 2025: revenue n/a, net income −$13.4M, EPS −$0.25
- Quarter ended Jun 30, 2025: revenue n/a, net income −$16.0M, EPS −$68.75
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.0M, EPS −$3.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.5M, EPS −$0.28
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.49M, EPS −$0.13
- Quarter ended Jun 30, 2024: revenue n/a, net income −$27.7M, EPS −$0.64
- Quarter ended Mar 31, 2024: revenue n/a, net income −$11.1M, EPS −$0.26
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.90M, EPS −$0.21
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.35M, EPS −$0.15
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.89M, EPS −$0.14
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.3M, EPS −$0.34
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.53M, EPS −$0.09
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.92M, EPS −$0.22
- Quarter ended Jun 30, 2022: revenue n/a, net income −$16.6M, EPS −$0.51
- Quarter ended Mar 31, 2022: revenue n/a, net income −$21.6M, EPS −$0.72
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$23.4M, EPS −$0.78
- Quarter ended Sep 30, 2021: revenue n/a, net income −$21.7M, EPS −$0.73
IRLA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$41.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$31.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$18.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$44.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$62.9M, share buybacks n/a
IRLA balance sheet
- Jun 30, 2026: cash $116M, total assets $124M, total liabilities $15.5M, shareholders' equity −$35.3M
- Mar 31, 2026: cash $18.2M, total assets $26.6M, total liabilities $11.0M, shareholders' equity $15.7M
- Dec 31, 2025: cash $5.81M, total assets $93.5M, total liabilities $129M, shareholders' equity −$35.7M
- Sep 30, 2025: cash $6.45M, total assets $110M, total liabilities $109M, shareholders' equity $1.06M
- Jun 30, 2025: cash $16.8M, total assets $117M, total liabilities $105M, shareholders' equity $11.7M
- Mar 31, 2025: cash $7.77M, total assets $107M, total liabilities $88.5M, shareholders' equity $18.6M
- Dec 31, 2024: cash $6.21M, total assets $114M, total liabilities $84.3M, shareholders' equity $30.1M
- Sep 30, 2024: cash n/a, total assets $127M, total liabilities $81.6M, shareholders' equity $44.9M
Is IRLA profitable?
No. QUINCE THERAPEUTICS INC lost $92.5M over the last four quarters.
What is IRLA's EPS?
Diluted earnings per share over the last four quarters were $61.06; −$12.31 in the latest quarter.